Levels of hyperphosphorylated tau were significantly lower in CTE cases compared to AD cases (hippocampus CTE vs. AD: pTau monomers 0.62 ± 0.70 vs. 2.56 ± 1.95, p = 0.04; pTau oligomers 0.46 ± 0.50 vs. 2.74 ± 3.41, p = 0.02; temporal cortex CTE vs. AD: pTau monomers 0.82 ± 0.69 vs. 5.32 ± 3.74, p = 0.03; pTau oligomers 0.77 ± 0.76 vs. 3.38 ± 2.82, p = 0.04; occipital cortex CTE vs. AD: pTau monomers 0.02 ± 0.006 vs. 5.46 ± 5.13, p = 0.03; pTau oligomers 0.01 ± 0.01 vs. 7.03 ± 7.22, p = 0.01) (Fig. 3c). The gene discussed is MAPT; the disease is Alzheimer disease.